Calidi Biotherapeutics annual ebitda
2024
2025
Calidi Biotherapeutics EBITDA Growth & History (CLDI)
Calidi Biotherapeutics's calculated EBITDA was −$18.6M for fiscal 2025.
View full Calidi Biotherapeutics company overviewCalidi Biotherapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$18.6M | $1.7M | — |
| 2024 | 2024-12-31 | −$20.2M | — | — |
Calidi Biotherapeutics quarterly ebitda
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.7M | $1.5M | — |
| Q1 2026 | 2026-03-31 | −$3.8M | $907,000 | — |
| Q4 2025 | 2025-12-31 | −$4.0M | $793,000 | — |
| Q3 2025 | 2025-09-30 | −$4.6M | — | — |
| Q2 2025 | 2025-06-30 | −$5.3M | — | — |
| Q1 2025 | 2025-03-31 | −$4.7M | — | — |
| Q3 2024 | 2024-09-30 | −$4.8M | — | — |
Calidi Biotherapeutics ebitda trends
Across the available reported history, Calidi Biotherapeutics's ebitda increased from −$20.2M to −$18.6M, a change of $1.7M. The latest reported quarter, Q2 2026, shows −$3.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Calidi Biotherapeutics filings at SEC.gov ↗